Results 121 to 130 of about 187,608 (218)
Background Little is known about the prevalence of and factors associated with Long COVID in patients with autoimmune rheumatic diseases (AIRDs). Methods We conducted a retrospective cohort study using data from the National Clinical Cohort Collaborative (N3C).
Namrata Singh +11 more
wiley +1 more source
A bioinformatics pipeline for the design of a SART3-targeted cancer vaccine with enhanced immunogenicity. [PDF]
Bayat Z +3 more
europepmc +1 more source
Abstract Aim The aim of this systematic review was to assess all available clinical data regarding the use of a single dose of basiliximab in solid organ transplantation compared to the standard double dosage, with particular interest in efficacy, safety and cost‐savings.
Alessio Provenzani +4 more
wiley +1 more source
Enhancing cancer vaccine efficacy via electrostatic engineering of an FcγR-targeted protein. [PDF]
Wu CC +6 more
europepmc +1 more source
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló +5 more
wiley +1 more source
Systemic Transcriptional Responses to Clinical Vaccine Formulations and Live-Attenuated Vaccination: Comparative Kinetics and Hypotheses for Therapeutic Cancer Vaccine Monitoring. [PDF]
Goldman CK.
europepmc +1 more source
Reversal of T cell exhaustion enables cancer vaccine efficacy in <i>BRCA1</i>-deficient ovarian cancer. [PDF]
Beziaud L +9 more
europepmc +1 more source
Efficacy, safety and cost‐effectiveness of CAR‐T therapy
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher +7 more
wiley +1 more source
Decoding RNA regulation: Challenges and opportunities for RNA‐based therapies in Europe
Abstract RNA‐based medicinal products represent a promising frontier in personalised medicine, offering sequence‐specific disease targeting at various molecular levels, yet their clinical translation in the European Union (EU) may be hindered by regulatory uncertainty around definitions and evidence requirements; this study therefore aims to identify ...
Olivia C. Lewis +4 more
wiley +1 more source

